Company News »

Acorda to Present New Analyses of Cimaglermin alfa (GGF2) Data at the 64th Annual ACC Scientific Session

Business Wire
Share on StockTwits
Published on

Acorda Therapeutics, Inc. (Nasdaq:ACOR) will present new analyses of data from a Phase 1 clinical trial of cimaglermin alfa (GGF2), an investigative drug for heart failure, at the American College of Cardiology 64th Annual Scientific Session and Expo (ACC). The meeting is being held in San Diego, CA, March 14-16.

“Cimaglermin alfa represents a novel approach to the development of treatment options for heart failure, potentially acting directly to strengthen the heart and improve its ability to pump blood. Current standard of care medications control blood pressure, fluid volume and neurohormonal activation that contribute to ongoing damage. Even with optimized care, the prognosis for people with advanced heart failure is poor. More effective treatments are needed for the 5.1 million Americans living with heart failure,” said Anthony Caggiano, M.D., Ph.D., Senior Vice President of Research and Development at Acorda. “In the Phase 1 trial, cimaglermin alfa improved ejection fraction, a measure of heart function, for as long as 90 days after a single dose. This improvement was observed on top of optimized medical therapy. Results from this trial helped inform our ongoing Phase 1b trial.”

“Sustained Improvements in Cardiac Function with Single Dose Cimaglermin Alfa (GGF2) in Human Left Ventricular Systolic Dysfunction” (Poster #1146-212) will be exhibited in Poster Hall B1 on Saturday, March 14th, 1:30-4:30. Daniel Lenihan, M.D., Professor of Medicine and Director, Clinical Research at the Vanderbilt University Medical Center, Division of Cardiovascular Medicine is the lead author and will present the poster.

More detailed information on the meeting can be found on the conference website:

Data from this study were previously presented at the American College of Cardiology 62nd Annual Scientific Session and Expo.

About Cimaglermin alfa

Cimaglermin alfa is a recombinant version of a naturally occurring growth factor that is important for cardiac development and function. In clinical development for heart failure, it may offer a unique mechanism. In preclinical studies, cimaglermin alfa acted at the level of the muscle cells, or cardiomyocytes, and is hypothesized to restore cardiomyocyte functions that are impaired in heart failure, potentially improving the heart’s ability to contract and pump blood. In preclinical studies and in a Phase 1 trial, cimaglermin alfa resulted in improved contractile function. Preclinical studies suggest that it may also protect the heart structure from acute and chronic stressors.

Cimaglermin alfa is also being investigated in preclinical studies as a treatment for neurological conditions such as stroke and peripheral nerve damage.

About Acorda Therapeutics

Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders.

Acorda markets three FDA-approved therapies, including AMPYRA(R) (dalfampridine) Extended Release Tablets, 10 mg, a treatment to improve walking in patients with multiple sclerosis (MS), as demonstrated by an increase in walking speed. The Company has one of the leading pipelines in the industry of novel neurological therapies. Acorda is currently developing a number of clinical and preclinical stage therapies. This pipeline addresses a range of disorders including post-stroke walking deficits, Parkinson’s disease, epilepsy, heart failure, MS and spinal cord injury.

For more information, please visit the Company’s website at:

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including the ability to realize the benefits anticipated from the Civitas transaction and to successfully integrate Civitas’ operations into our operations; our ability to successfully market and sell Ampyra in the U.S.; third party payers (including governmental agencies) may not reimburse for the use of Ampyra or our other products at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; the risk of unfavorable results from future studies of Ampyra or from our other research and development programs, including CVT-301, Plumiaz, or any other acquired or in-licensed programs; we may not be able to complete development of, obtain regulatory approval for, or successfully market CVT-301, Plumiaz, or any other products under development; we may need to raise additional funds to finance our expanded operations and may not be able to do so on acceptable terms; the occurrence of adverse safety events with our products; delays in obtaining or failure to obtain regulatory approval of or to successfully market Fampyra outside of the U.S. and our dependence on our collaboration partner Biogen Idec in connection therewith; competition; failure to protect our intellectual property, to defend against the intellectual property claims of others or to obtain third party intellectual property licenses needed for the commercialization of our products; and, failure to comply with regulatory requirements could result in adverse action by regulatory agencies.

These and other risks are described in greater detail in Acorda Therapeutics’ filings with the Securities and Exchange Commission. Acorda may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Forward-looking statements made in this release are made only as of the date hereof, and Acorda disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this release.

Share on StockTwits